8-K: IRulya Therapeutics Emerges Post-Merger with Strong Leadership

Quince Therapeutics rebrands as IRulya Therapeutics, announces key executive and board appointments, and reaffirms focus on LAM-001 development with a projected cash runway through 2028.

Summary

• Quince Therapeutics, Inc. has officially changed its name to IRulya Therapeutics Inc., effective October 9, 2026, and will trade under the ticker IRLA starting October 12, 2026.
• The company has appointed Brigette Roberts, M.D., as CEO, John Militello, CPA, as CFO, and Keith Fandrick, Ph.D., as COO.
• Dirk Thye and Brendan Hannah have resigned from their executive positions.
• The Board of Directors has been expanded with four new members: Catherine M. Bonuccelli, M.D., Leone Patterson, James Valentine, J.D., M.H.S., and Drayton Wise.
• IRulya Therapeutics will focus on the clinical development of LAM-001, an inhaled formulation of rapamycin, for pulmonary diseases including PH-ILD, BOS, and SAPH.
• The company reported a cash balance of $116 million as of June 30, 2026, which is expected to fund operations through the end of 2028.
• Stockholder approval was obtained for the conversion of Series C preferred stock and exercise of warrants related to the May 2026 merger with Orphai Therapeutics and concurrent private placement.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, marked by a strategic rebranding, key leadership appointments, and a clear clinical and financial outlook, indicating forward momentum.

Positives

• Successful rebranding to IRulya Therapeutics Inc. with a new ticker symbol (IRLA) and Nasdaq Capital Market listing.
• Strengthening of the executive team with experienced leaders: Brigette Roberts (CEO), John Militello (CFO), and Keith Fandrick (COO).
• Expansion of the Board of Directors with individuals possessing significant biopharmaceutical and regulatory expertise.
• Clear strategic focus on advancing LAM-001 for multiple pulmonary indications (PH-ILD, BOS, SAPH).
• Projected cash runway through the end of 2028, providing financial stability for ongoing clinical development.
• Completion of Series C preferred stock conversion and warrant exercise, simplifying the capital structure.
• Positive clinical data from a Phase 2a study in PH-ILD patients showing meaningful improvements.

Negatives

• Resignation of previous CEO Dirk Thye and COO Brendan Hannah.
• The company is still in the clinical stage, with LAM-001 not yet approved for any indication.
• The success of LAM-001 is dependent on future clinical trial results, which carry inherent risks.

Risks

• Clinical trial results may not be indicative of future results, especially in larger populations.
• Potential safety and other complications related to LAM-001.
• The ability to obtain and maintain regulatory approval for LAM-001.
• Competition in the company's industry.
• The scope, progress, and expansion of developing LAM-001.
• Market acceptance of LAM-001 compared to alternative therapies.
• The company's ability to attract or retain key management, board members, and personnel.
• General macroeconomic and geopolitical conditions impacting the business.

Future Outlook

The company anticipates its cash balance will fund operations through the end of 2028, supporting anticipated clinical data readouts from Phase 2 studies of LAM-001 in BOS, PH-ILD, and SAPH. Data from the PH-ILD Phase 2b trial is expected in Q1 2028, data from the BOS Phase 2 trial in Q1 2027, and a Phase 2 study in SAPH is planned for 4Q26 with data anticipated in Q4 2028.

Management Comments

• "Today marks an important milestone as we introduce our newly transformed company as IRulya Therapeutics. With a focus on the clinical development of LAM-001, a potentially first in class, one puff once daily dry powder inhaled (DPI) formulation of rapamycin, we believe we have an opportunity to change the current treatment paradigm for serious pulmonary diseases. Importantly, our strengthened balance sheet positions us well to advance LAM-001 through data readouts across Phase 2 clinical studies in three pulmonary indications: BOS, PH-ILD, and SAPH."
• Brigette Roberts, M.D., Chief Executive Officer of IRulya Therapeutics.

Industry Context

StockSavvy.ai notes that the rebranding and leadership changes align with typical post-merger integration strategies in the biopharmaceutical sector. The intensified focus on LAM-001 and its potential in rare pulmonary diseases reflects a common industry trend of targeting niche markets with high unmet needs.

Comparison to Industry Standards

• The cash balance of $116 million is substantial for a clinical-stage biopharmaceutical company, providing a runway through 2028, which is generally considered a strong position for advancing multiple Phase 2 trials.
• The appointment of experienced executives and directors with backgrounds at companies like AstraZeneca, GSK, Novartis, and Rocket Pharmaceuticals aligns with industry standards for building robust leadership teams.
• The focus on rare pulmonary diseases like PH-ILD, BOS, and SAPH is consistent with industry efforts to address underserved patient populations where significant therapeutic advancements can be made.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The rebranding and new ticker symbol may affect trading dynamics. The conversion of preferred stock and warrants simplifies the capital structure. Continued focus on LAM-001 development offers potential for future value creation.
• Employees: Key management changes and the integration of operations post-merger will impact employees. Continued employment terms for some key personnel are outlined.
• Creditors: The company's cash balance and projected runway suggest financial stability, which is positive for creditors.

Next Steps

• Trading on the Nasdaq Capital Market under the new ticker symbol IRLA, effective October 12, 2026.
• Advancing LAM-001 through Phase 2 clinical studies in BOS, PH-ILD, and SAPH.
• Anticipated data readouts from Phase 2 trials in BOS (Q1 2027), PH-ILD (Q1 2028), and SAPH (Q4 2028).
• Initiation of a Phase 2 study in SAPH in 4Q26.

Key Dates

Recommendation

The rebranding, leadership changes, and clear clinical focus are positive developments. However, the company remains in the clinical stage with significant binary risk associated with LAM-001's success. The substantial cash runway provides a buffer, but investors should await further clinical data before considering a more aggressive stance. A 'hold' reflects the current balance of potential upside and inherent risks.

Keywords

IRulya Therapeutics, LAM-001, pulmonary disease, rapamycin, mTOR inhibitor, PH-ILD, BOS, SAPH